Shares of ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) shot up 3.7% during trading on Friday . The company traded as high as $4.02 and last traded at $3.94. 901,709 shares changed hands during trading, a decline of 81% from the average session volume of 4,824,901 shares. The stock had previously closed at $3.80.
Analyst Upgrades and Downgrades
Separately, Piper Sandler decreased their price objective on shares of ImmunityBio from $6.00 to $4.75 and set a "neutral" rating on the stock in a report on Monday, August 19th.
Read Our Latest Stock Report on ImmunityBio
ImmunityBio Stock Up 3.9 %
The stock has a market cap of $2.73 billion, a PE ratio of -3.62 and a beta of 1.07. The business's fifty day moving average is $5.30 and its 200 day moving average is $5.76.
Institutional Trading of ImmunityBio
Several large investors have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in ImmunityBio by 46.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 28,105 shares of the company's stock valued at $141,000 after buying an additional 8,932 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in ImmunityBio by 408.3% during the 4th quarter. Russell Investments Group Ltd. now owns 14,766 shares of the company's stock valued at $74,000 after buying an additional 11,861 shares during the last quarter. Victory Capital Management Inc. grew its holdings in ImmunityBio by 25.8% during the 4th quarter. Victory Capital Management Inc. now owns 17,642 shares of the company's stock valued at $89,000 after buying an additional 3,613 shares during the last quarter. Amalgamated Bank grew its holdings in ImmunityBio by 21.9% during the 4th quarter. Amalgamated Bank now owns 17,752 shares of the company's stock valued at $89,000 after buying an additional 3,186 shares during the last quarter. Finally, Private Advisor Group LLC acquired a new stake in ImmunityBio during the 4th quarter valued at $53,000. 8.58% of the stock is currently owned by institutional investors and hedge funds.
About ImmunityBio
(
Get Free Report)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
Further Reading
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
